Curated News
By: NewsRamp Editorial Staff
May 06, 2026

Tonix Pharma Gains Major Coverage for Fibromyalgia Drug TONMYA

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Tonix's TONMYA gains coverage for 35M commercial lives, boosting market access against competitors in fibromyalgia treatment.
  • Tonix secured an agreement with a GPO for TONMYA, covering ~35M lives under standard utilization management criteria.
  • Tonix expands patient access to TONMYA, a non-opioid fibromyalgia treatment, potentially improving quality of life for millions.
  • TONMYA is the first new fibromyalgia drug in 15 years, now covered for 20% of the U.S. commercial market.

Impact - Why it Matters

This news matters because it marks a crucial step in expanding access to the first new fibromyalgia treatment in over 15 years, offering a non-opioid option for millions of patients. For investors, the agreement with a major group purchasing organization covering 35 million lives could significantly boost Tonix Pharmaceuticals' commercial revenue and validates the market potential of TONMYA. Additionally, Tonix's broader pipeline of CNS and immunology therapies positions it as a key player in addressing high unmet medical needs, making this a development worth watching.

Summary

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced a significant agreement with a leading group purchasing organization, effective May 1, 2026, to provide coverage for TONMYA (cyclobenzaprine HCl sublingual tablets) to approximately 35 million U.S. commercial lives, representing about 20% of the commercial market. This non-opioid treatment for fibromyalgia, which received FDA approval as the first new therapy for the condition in over 15 years, will be covered under standard utilization management criteria. The company is actively pursuing additional coverage across commercial and government channels, with existing Medicaid coverage in 38 states covering roughly 55 million lives. This milestone expands patient access to TONMYA, a key product in Tonix’s CNS portfolio.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments for high unmet medical needs. Beyond TONMYA, the company’s CNS commercial infrastructure supports marketed acute migraine products Zembrace SymTouch and Tosymra. Tonix is also evaluating TONMYA’s potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder. The CNS pipeline includes TNX-2900, Phase 2 ready for Prader-Willi syndrome. In immunology, Tonix is advancing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention. These efforts underscore Tonix’s commitment to addressing diverse therapeutic areas.

This development is particularly noteworthy for investors and patients. The agreement enhances TONMYA’s market access, potentially driving revenue growth for Tonix while offering a non-opioid alternative for fibromyalgia sufferers. The company’s diversified pipeline, spanning CNS and immunology, provides multiple catalysts. For the latest news and updates relating to TNXP, visit the company’s newsroom at https://ibn.fm/TNXP. The press release was disseminated via InvestorWire, a platform within IBN’s Dynamic Brand Portfolio, which offers wire-grade press release syndication and enhanced distribution to a vast network of outlets and social media followers. For more information, visit InvestorWire.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharma Gains Major Coverage for Fibromyalgia Drug TONMYA

blockchain registration record for this content.